JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

13.15 -1.72

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.88

Máximo

13.4

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	5.076 67.147
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+49.7% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.3B
Apertura anterior	14.87
Cierre anterior	13.15

Noticias sobre sentimiento de mercado

By Acuity

50%

186 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 may 2026, 21:36 UTC

Adquisiciones, fusiones, absorciones

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 may 2026, 20:40 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 may 2026, 18:37 UTC

Principales Movimientos del Mercado

Senseonic Shares Slide on Underwritten Offering Price

1 may 2026, 16:46 UTC

Principales Movimientos del Mercado

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

1 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 may 2026, 20:42 UTC

Ganancias

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 may 2026, 19:33 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 may 2026, 19:33 UTC

Charlas de Mercado

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 may 2026, 19:18 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 may 2026, 19:13 UTC

Charlas de Mercado

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 may 2026, 18:36 UTC

Ganancias

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 may 2026, 18:35 UTC

Ganancias

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 may 2026, 18:28 UTC

Ganancias

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 may 2026, 18:27 UTC

Charlas de Mercado

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 may 2026, 18:14 UTC

Adquisiciones, fusiones, absorciones

Barclays Completes Acquisition of Best Egg

1 may 2026, 18:04 UTC

Ganancias

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 may 2026, 17:43 UTC

Charlas de Mercado

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 may 2026, 17:37 UTC

Charlas de Mercado

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 may 2026, 17:30 UTC

Charlas de Mercado

Ganancias

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 may 2026, 17:28 UTC

Charlas de Mercado

Ganancias

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 may 2026, 17:21 UTC

Charlas de Mercado

Ganancias

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 may 2026, 17:19 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 may 2026, 16:38 UTC

Charlas de Mercado

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 may 2026, 16:23 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

1 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 may 2026, 16:15 UTC

Ganancias

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1 may 2026, 16:11 UTC

Charlas de Mercado

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1 may 2026, 16:04 UTC

Ganancias

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

49.7% repunte

Estimación a 12 Meses

Media 20 USD 49.7%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

186 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.